HoLEP Double-n Technology Promising for Benign Prostatic Hyperplasia
By Elana Gotkine HealthDay Reporter
THURSDAY, Feb. 6, 2025 -- For men with benign prostatic hyperplasia (BPH), transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology shows promise for improving urinary symptoms while better preserving ejaculatory function, according to a study published online Jan. 10 in the World Journal of Urology.
Zhixiang Gao, from Zhangjiagang Hospital Affiliated to Soochow University in Suzhou, China, and colleagues conducted a multicenter, prospective, single-blind, randomized controlled trial involving sexually active men with BPH. Participants were randomly allocated to standard HoLEP, single-n technology, and innovative double-n technology (groups A, B, and C, respectively). A total of 139 participants completed the study.
The researchers found that all groups had significant improvements in maximum urinary flow rate and the International Prostate Symptom Score. Across all groups, there were initial declines in International Index of Erectile Function scores, stabilizing to baseline by three months, with no additional improvement observed. Modest antegrade ejaculation rates were seen in group A, starting at 15.4 percent at three months and reaching 23.1 percent at 12 months. In groups B and C, significant improvement was seen, with antegrade ejaculation rates increasing from 31.8 to 45.5 percent and from 57.8 to 77.8 percent, respectively. Group A had 100 percent semen reduction at three months, decreasing to 77.8 percent at 12 months. A similar trend was seen in Group B (100 and 68.2 percent, respectively), while a more pronounced decline was seen in Group C, from 84.6 to 37.1 percent, respectively.
"The Double-n HoLEP represents a significant step forward in the surgical management of BPH, especially for patients concerned about preserving sexual function postoperatively," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Blue Laser Vaporization Effective for Benign Prostatic Hyperplasia
TUESDAY, April 8, 2025 -- Blue laser vaporization alleviates lower urinary tract symptoms while preserving sexual function in patients undergoing benign prostatic hyperplasia...
NeuroSAFE Improves Erectile Function After Radical Prostatectomy
THURSDAY, April 3, 2025 -- Use of the NeuroSAFE technique, a standardized frozen section analysis that enables accurate real-time detection of positive surgical margins during...
Aquablation Appears to Be Safe, Effective for Enlarged Prostates
TUESDAY, March 25, 2025 -- The Aquablation water-based surgical procedure is safe and effective for use with enlarged prostates compared with laser surgery, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.